Pregabalin for the Treatment of Vulvodynia
Information source: The Cleveland Clinic
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Vulvodynia; Vulvar Vestibulitis
Intervention: pregabalin (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: The Cleveland Clinic Official(s) and/or principal investigator(s): Beri M Ridgeway, MD, Principal Investigator, Affiliation: The Cleveland Clinic Matthew D Barber, MD, MHS, Study Director, Affiliation: The Cleveland Clinic
Summary
The purpose of this study is to determine whether pregabalin is effective in the treatment
of vulvodynia.
Clinical Details
Official title: Pregabalin (Lyrica) for the Treatment of Vulvodynia: A Randomized, Double-blinded, Placebo-controlled Cross-over Study
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Reduction in average pain over the last 7 days of each arm using an 11-point scale (0-10)
Secondary outcome: Effect on quality of life as measured by the Brief Pain Inventory, the Medical Outcomes Study Short-form 36 (SF-36)Effect on sleep based on MOS sleep scores Tolerability of pregabalin in this population Effect on anxiety and depression in women with vulvodynia based on the Kessler Psychological Distress Scale (K10)
Detailed description:
Vulvodynia is a condition exclusive to women and involves mostly burning, rawness, and
itching of the external genitourinary tract that often results in painful intercourse.
Vulvodynia rarely results in severe morbidity or mortality; rather it causes symptoms of the
lower genital, urinary, and gastrointestinal tracts that can impact a woman's daily
activities and negatively affect her quality of life.
Despite the fact that chronic vulvovaginal symptoms are one of the most common reasons for
visits to a gynecology clinic, epidemiologic studies of the incidence and prevalence of
these conditions are rare and available population-based studies are limited. Approximately
16% of women will experience chronic vulvar pain at some point in their lifetime; with 5%
experiencing this condition before age 25.
Treatment approaches include behavioral changes, medical management, and surgery,
specifically vulvar vestibulectomy. Prior to considering surgical intervention, all
medical treatment options should be exhausted. Although vulvodynia is quite prevalent and
can be a debilitating disease, there are few studies that critically evaluate the medical
management of vulvodynia. Pregabalin is an anticonvulsant that has proven efficacy in the
treatment of diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia. Anecdotal data
and one case report provide hope that this medication may also be effective in the treatment
of vulvodynia.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Adult women age 18 or greater
- Vulvodynia as defined as chronic vulvar discomfort or pain, characterized by burning,
stinging, irritation or rawness of the female genitalia in cases in which there is no
infection or skin disease of the vulva or vagina causing these symptoms. Pain may be
constant or intermittent, localized or diffuse. Symptoms may be consistent with
either Generalized Vulvodynia (diffuse or focal and constant or unremitting symptoms
present in the labia majora, labia minora, and/or the vestibule that are not
necessarily caused by touch or pressure to the vulva) or Vulvar Vestibulitis Syndrome
(pain only in the vestibule and only during or after touch or pressure is applied).
- Pain ≥ 40 on 100mm VAS
- Practicing reliable form of birth control defined as sterilization, hormonal
contraception, abstinence, IUD
- Must be able to attend follow up visits and are not likely to leave the area during
the study period
Exclusion Criteria:
- Atrophic vaginitis, active bacterial vaginosis, yeast, and herpetic infections
- Current pregnancy diagnosed by positive serum or urine pregnancy test
- Current breastfeeding
- Seizure disorder or other chronic neurologic disease
- Diagnosis of chronic renal insufficiency defined as creatinine >1. 4
- Unable to read and speak English
- Contraindication to pregabalin or history of prior use of pregablin
- Chronic narcotic or benzodiazepine use
- Chronic alcohol abuse
- Other chronic pain disorders, (ie. chronic pelvic pain, endometriosis, interstitial
cystitis)
- Chronic neuropathic pain or anything affecting sensation (ie. MS, stroke)
Locations and Contacts
Cleveland Clinic, Cleveland, Ohio 44195, United States
Additional Information
Starting date: February 2009
Last updated: August 22, 2013
|